JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices things up with Arrakis; Sage...

cafead

Administrator
Staff member
  • cafead   Jan 11, 2022 at 12:12: PM
via Welcome to Day 2 of the annual J. P. Morgan Healthcare Conference, gone virtual once more.

Here's your need to know. The deals began to flow as Amgen announced a team-up with Arrakis Therapeutics to develop a new class of RNA-targeting medicines, and Roche delivered a sizable investment in the liquid biopsy developer Freenome.

article source